Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Imiquimod Creams for Actinic Keratoses
NCT00605176Phase 3Completed
- Sponsor
- Graceway Pharmaceuticals
- Start
- Jan 2008
- Primary completion
- Jul 2008
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of imiquimod in actinic keratosis (AK) (3 arms), sponsored by Graceway Pharmaceuticals. Primary endpoint: Number of Participants With Complete Clearance of AK Lesions at 14 weeks. Started Jan 2008; status: completed.
02
Drugs
imiquimod
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT00605176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00605176.